A New Approach for Diabetic Macular Edema Treatment: Review of Clinical Practice Results with 0.19 mg Fluocinolone Acetonide Intravitreal Implant Including Vitrectomized Eyes
- 3 Downloads
Purpose of Review
Fluocinolone acetonide is a synthetic fluorinated glucocorticoid. It has selective and potent agonist properties by binding to the cytosolic glucocorticoid receptor with high affinity; it is devoid of mineralocorticoid activity. Two extended-release (i.e., lasting up to 3 years) drug delivery systems containing fluocinolone acetonide (FAc) have been approved by the FDA for intravitreal use: Retisert® (Bausch&Lomb, NJ, USA) and Iluvien® (Alimera Sciences, Atlanta, USA). The former contains 0.59 mg of FAc, which is approved for the treatment of chronic non-infectious posterior segment uveitis. The latter contains a dose of 0.19 mg of FAc and is approved for the treatment of diabetic macular edema, and here we review the results published in the clinical literature relating to its use in the treatment of diabetic macular edema (DME).
The 0.19-mg FAc implant (Iluvien®) is a new approved treatment approach for DME. It is a non-biodegradable implant that continuously releases a microdose of FAc into the vitreous cavity for up to 3 years. It is effective in chronic DME with the added value of decreasing the treatment burden of multiple intravitreal injections. Recently, clinical practice studies are reporting its efficacy and safety profile (intraocular pressure rise and cataract), as well as its use in clinical setting not included in clinical trial such as vitrectomized eyes.
The FAc implant has demonstrated in clinical practice results that mirror the results of the clinical trials efficacy wise. Regarding its safety profile, cataract is a common complication; however, intraocular pressure rises may be lower than the ones reported in trials. The implant has shown effectiveness in vitrectomized eyes. An increasing evidence of real-world studies has supported utility of the implant in DME patients. Its extended-release format for up to 3 years benefits the patient and carer as it means fewer injections and visits to the clinic.
KeywordsDiabetic macular edema Intravitreal corticosteroids Long-acting corticosteroids, diabetic retinopathy
This manuscript received financial support the National Institutes of Health Center Core Grant (P30 EY014801), research to prevent blindness unrestricted grant.
Compliance with Ethical Standards
Conflict of Interest
Raquel Estebainha declares no potential conflicts of interest.
Raquel Goldhardt is section editor of the Retina section of Current Ophthalmology Reports.
Manuel Falcão has received travel grants from Alimera, Allergan, Bayer, and Novartis and received lecture honoraria from Alimera and Bayer.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
- 1.The Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;150218140025008.Google Scholar
- 5.Yau JWY, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556–64 Available from: http://care.diabetesjournals.org/cgi/doi/10.2337/dc11-1909.CrossRefGoogle Scholar
- 7.Minassian D, Owens D, Reidy AMP. Diabetic macular oedema and related sight loss at first screening for eye disease. The Wales Diabetic Retinopathy Screening Service (WDRSS). UK Vision Strategy. 2010;3:2008.Google Scholar
- 11.Haritoglou C, Neubauer AS, Kernt M. Fluocinolone acetonide and its potential in the treatment of chronic diabetic macular edema. Clin Ophthalmol. 2013;7:503–9 Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3595182&tool=pmcentrez&rendertype=abstract.CrossRefGoogle Scholar
- 12.Nguyen QD, Shah SM, Heier JS, Do DV, Lim J, Boyer D, et al. Primary end point (six months) results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study. Ophthalmology. 2009;116(11):2175–2181.e1 Available from: http://linkinghub.elsevier.com/retrieve/pii/S0161642009004102.CrossRefGoogle Scholar
- 17.Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013;120(10):2013–22. https://doi.org/10.1016/j.ophtha.2013.02.034.CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Figueira J, Henriques J, Amaro M, Rosas V, Alves D, Cunha-Vaz J. A nonrandomized, open-label, multicenter, phase 4 pilot study on the effect and safety of ILUVIEN® in chronic diabetic macular edema patients considered insufficiently responsive to available therapies (RESPOND). Ophthalmic Res. 2017;57(3):166–72.CrossRefGoogle Scholar
- 21.Daruich A, Matet A, Behar-Cohen F. Sustained-release steroids for the treatment of diabetic macular edema. Curr Diab Rep. 2015;15(11).Google Scholar
- 22.Massin P, Erginay A, Dupas B, Couturier A, Tadayoni R. Efficacy and safety of sustained-delivery fluocinolone acetonide intravitreal implant in patients with chronic diabetic macular edema insufficiently responsive to available therapies: a real-life study. Clin Ophthalmol. 2016;10:1257–64.CrossRefGoogle Scholar
- 23.Nurözler Tabakcı B, Ünlü N. Corticosteroid treatment in diabetic macular edema. Türk Oftalmol Derg. 2017;47(3):156–60 Available from: http://cms.galenos.com.tr/FileIssue/6/1205/article/156-160-ing.pdf.CrossRefGoogle Scholar
- 25.Hussain RM, Ciulla TA. Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy. Expert Opin Biol Ther. 2016;16(3):365–74 Available from: http://www.tandfonline.com/doi/full/10.1517/14712598.2016.1131265.CrossRefGoogle Scholar
- 27.Dong N, Xu B, Wang B, Chu L. Study of 27 aqueous humor cytokines in patients with type 2 diabetes with or without retinopathy. Mol Vis. 2013;19(April):1734–46 Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3733907&tool=pmcentrez&rendertype=abstract.PubMedPubMedCentralGoogle Scholar
- 30.Campochiaro PA, Nguyen QD, Hafiz G, Bloom S, Brown DM, Busquets M, et al. Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants. Ophthalmology. 2013;120(3):583–7. https://doi.org/10.1016/j.ophtha.2012.09.014.CrossRefPubMedPubMedCentralGoogle Scholar
- 31.Pessoa B, Coelho J, Correia N, Ferreira N, Beirão M, Meireles A. Fluocinolone acetonide intravitreal implant 190 μg (ILUVIEN®) in vitrectomized versus nonvitrectomized eyes for the treatment of chronic diabetic macular edema. Ophthalmic Res. 2018 [cited 2018 Aug 23];59(2):68–75. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29248913.CrossRefGoogle Scholar
- 32.Meireles A, Goldsmith C, El-Ghrably I, Erginay A, Habib M, Pessoa B, et al. Efficacy of 0.2 μg/day fluocinolone acetonide implant (ILUVIEN) in eyes with diabetic macular edema and prior vitrectomy. Eye. 2017;31(5):684–90. https://doi.org/10.1038/eye.2016.303.CrossRefPubMedPubMedCentralGoogle Scholar
- 34.Campochiaro PA, Brown DM, Pearson A, Ciulla T, Boyer D, Holz FG, et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology. 2011;118(4):626–635.e2 Available from: http://linkinghub.elsevier.com/retrieve/pii/S0161642010013813.CrossRefGoogle Scholar
- 35.Campochiaro PA, Brown DM, Pearson A, Chen S, Boyer D, Ruiz-Moreno J, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012;119(10):2125–32. https://doi.org/10.1016/j.ophtha.2012.04.030.CrossRefPubMedPubMedCentralGoogle Scholar
- 36.Wykoff CC, Chakravarthy U, Campochiaro PA, Bailey C, Green K, Cunha-Vaz J. Long-term effects of intravitreal 0.19 mg fluocinolone acetonide implant on progression and regression of diabetic retinopathy. Ophthalmology. 2017;124(4):440–9. https://doi.org/10.1016/j.ophtha.2016.11.034.CrossRefPubMedGoogle Scholar
- 41.Chakravarthy U, Taylor SR, Koch FHJ, Castro de Sousa JP, Bailey C. Changes in intraocular pressure after intravitreal fluocinolone acetonide (ILUVIEN): real-world experience in three European countries. Br J Ophthalmol. 2018 21 [cited 2018 Oct 6];bjophthalmol-2018-312284. Available from: http://bjo.bmj.com/lookup/doi/10.1136/bjophthalmol-2018-312284
- 42.Bertelmann T, Schulze S. Long-term follow-up of patient with diabetic macular edema receiving fluocinolone acetonide intravitreal implant. Ophthalmol Therapy. 2015;4(1):51–8 Available from: http://link.springer.com/10.1007/s40123-015-0028-0.CrossRefGoogle Scholar
- 45.Currie CJ, Holden SE, Berni E, Owens DR. Evaluation of the clinical effectiveness of fluocinolone acetonide 190 μg intravitreal implant in diabetic macular edema: a comparison between study and fellow eyes. Curr Med Res Opin. 2017;33:19–31. https://doi.org/10.1080/03007995.2017.1366659.CrossRefPubMedGoogle Scholar